Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device.
Wehmeier PM, Schacht A, Wolff C, Otto WR, Dittmann RW, Banaschewski T. Wehmeier PM, et al. J Child Adolesc Psychopharmacol. 2011 Oct;21(5):433-44. doi: 10.1089/cap.2010.0142. J Child Adolesc Psychopharmacol. 2011. PMID: 22040189 Clinical Trial.
Global impression of perceived difficulties in children and adolescents with attention-deficit/hyperactivity disorder: reliability and validity of a new instrument assessing perceived difficulties from a patient, parent and physician perspective over the day.
Wehmeier PM, Schacht A, Dittmann RW, Döpfner M. Wehmeier PM, et al. Child Adolesc Psychiatry Ment Health. 2008 May 28;2(1):10. doi: 10.1186/1753-2000-2-10. Child Adolesc Psychiatry Ment Health. 2008. PMID: 18507847 Free PMC article.
Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS).
Wehmeier PM, Schacht A, Lehmann M, Dittmann RW, Silva SG, March JS. Wehmeier PM, et al. Child Adolesc Psychiatry Ment Health. 2008 May 28;2(1):11. doi: 10.1186/1753-2000-2-11. Child Adolesc Psychiatry Ment Health. 2008. PMID: 18507848 Free PMC article.
Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings.
Dittmann RW, Wehmeier PM, Schacht A, Lehmann M, Lehmkuhl G. Dittmann RW, et al. Among authors: wehmeier pm. Atten Defic Hyperact Disord. 2009 Dec;1(2):187-200. doi: 10.1007/s12402-009-0011-5. Epub 2009 Sep 23. Atten Defic Hyperact Disord. 2009. PMID: 20234829 Free PMC article. Clinical Trial.
Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder.
Wehmeier PM, Schacht A, Dittmann RW, Helsberg K, Schneider-Fresenius C, Lehmann M, Bullinger M, Ravens-Sieberer U. Wehmeier PM, et al. Qual Life Res. 2011 Jun;20(5):691-702. doi: 10.1007/s11136-010-9803-5. Epub 2010 Dec 7. Qual Life Res. 2011. PMID: 21136299 Clinical Trial.
Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM. Dittmann RW, et al. Among authors: wehmeier pm. J Child Adolesc Psychopharmacol. 2011 Apr;21(2):97-110. doi: 10.1089/cap.2009.0111. Epub 2011 Apr 13. J Child Adolesc Psychopharmacol. 2011. PMID: 21488751 Clinical Trial.
52 results